Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Titan Pharma (TTNP) Reports Q2 Loss of $0.11, Revenues Beat
November 14, 2018 4:21 PM ESTTitan Pharma (NASDAQ: TTNP) reported Q2 EPS of ($0.11), versus ($0.20) reported last year. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $100 thousand.
"In order to maximize the significant market opportunity represented by our lead product, Probuphine®, we were... More



